Evidence map›Paper›PMID 41200593›Full record

ReviewCureus2025

Infectious Disease Surveillance in the Era of Big Data and AI: Opportunities and Pitfalls.

Courage O Idahor, Ena-Jane O Esomu, Ndidiamaka Ogbonna, Zaafirah Momoh, Omo A Ogbeide, Osamagbe Ikhu-Omoregbe, Augustina Adigwe, Osayuwamen M Erhabor, Osamagbe Osaghae, Nosa Orons

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Courage O IdahorEmergency Medicine, Nottingham University Hospitals NHS Trust, Nottingham, GBR.
Ena-Jane O EsomuSurgery, University of Benin, Benin City, NGA.
Ndidiamaka OgbonnaFamily Medicine, Edo State University Uzairue, Uzairue, NGA.
Zaafirah MomohObstetrics and Gynecology, Asaba Specialist Hospital, Asaba, NGA.
Omo A OgbeideGeneral Practice, NES Healthcare UK, Aylesbury, GBR.
Osamagbe Ikhu-OmoregbeInternal Medicine, University of Benin, Benin City, NGA.
Augustina AdigweGeneral Medicine, Zaporozhye State Medical University, Zaporozhye, UKR.
Osayuwamen M ErhaborInternal Medicine, University of Benin, Benin City, NGA.
Osamagbe OsaghaeInternal Medicine, University of Benin, Benin City, NGA.
Nosa OronsEmergency Medicine, University of Benin, Benin City, NGA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The landscape of infectious disease surveillance (IDS) is undergoing a profound shift, driven by the rapid emergence of big data and artificial intelligence (AI). Traditional surveillance systems, while foundational to public health, are increasingly limited by delayed reporting, data silos, and fragmented information flows. In response to these limitations, the integration of AI and big data offers new possibilities for enhancing disease detection, monitoring, and response strategies on both local and global scales. This review explores the potential of AI-enabled tools and big data systems to support early outbreak detection, real-time surveillance, and predictive modeling. These technologies facilitate the synthesis of diverse datasets, including clinical, genomic, geospatial, and environmental information, enabling a more holistic understanding of disease patterns. Additionally, AI contributes to improved diagnostic accuracy and optimized resource allocation, which are critical during public health emergencies. However, the adoption of these technologies has not been without challenges. Concerns about data privacy, equity in access, algorithmic bias, and over-reliance on automated systems present significant ethical and operational hurdles. In low-resource settings, limited digital infrastructure further complicates implementation. The review also highlights real-world applications from recent outbreaks, such as COVID-19, influenza, and Zika, to demonstrate both the promise and the limitations of AI-driven surveillance. To move forward responsibly, public health systems must adopt a balanced approach that integrates AI capabilities with human oversight. Strategic investment, cross-sector collaboration, and the development of clear ethical frameworks are essential to unlocking the full potential of big data and AI in infectious disease surveillance.

Indexed as

artificial intelligence in medicinebig datageospatial datainfectious disease surveillancemachine learning (ml)

Identifiers

PMID41200593
PMCPMC12587752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.